Safety and efficacy of Elotuzumab combination therapy for patients with multiple myeloma: A systematic review and meta-analysis.

IF 2.9 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2023-03-01 DOI:10.1080/14737140.2023.2169139

Maryam Noori, Farimah Fayyaz, Nima Rezaei

{"title":"Safety and efficacy of Elotuzumab combination therapy for patients with multiple myeloma: A systematic review and meta-analysis.","authors":"Maryam Noori, Farimah Fayyaz, Nima Rezaei","doi":"10.1080/14737140.2023.2169139","DOIUrl":null,"url":null,"abstract":"Objective: We evaluate the efficacy and safety of Elotuzumab, an immunostimulatory monoclonal antibody, in combination with concomitant treatment regimens for multiple myeloma (MM) patients.Research design and methods: PubMed, Scopus, Web of Science, and EMBASE databases were searched systematically up to 2 August 2022.Results: Five randomized control trials with a total of 1,763 participants were included. Elotuzumab combination therapy improved PFS and OS by 14% (hazard ratio [HR] 0.86) and 20% (HR 0.80), respectively, relative to the non-Elotuzumab regimen. Adding Elotuzumab to Lenalidomide plus Dexamethasone regimen (HR 0.82) or Pomalidomide plus Dexamethasone regimen (HR 0.54) were considered to improve the PFS. Meanwhile, the risk of disease progression was only reduced for patients with relapsed/refractory MM (HR 0.70) but not for newly diagnosed/untreated MM (HR 0.93). Finally, the risk of serious adverse events (RR 1.12) and the risk of infection (RR 1.09) and cardiac disorders (RR 1.32) were higher for the experimental group compared to the control group.Conclusions: Our findings showed that Elotuzumab combination therapy prolonged OS and PFS compared to non-Elotuzumab treatments in patients with MM. However, further investigations are required to establish the most effective combination of the Elotuzumab regimen.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 3","pages":"327-338"},"PeriodicalIF":2.9000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2023.2169139","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: We evaluate the efficacy and safety of Elotuzumab, an immunostimulatory monoclonal antibody, in combination with concomitant treatment regimens for multiple myeloma (MM) patients.

Research design and methods: PubMed, Scopus, Web of Science, and EMBASE databases were searched systematically up to 2 August 2022.

Results: Five randomized control trials with a total of 1,763 participants were included. Elotuzumab combination therapy improved PFS and OS by 14% (hazard ratio [HR] 0.86) and 20% (HR 0.80), respectively, relative to the non-Elotuzumab regimen. Adding Elotuzumab to Lenalidomide plus Dexamethasone regimen (HR 0.82) or Pomalidomide plus Dexamethasone regimen (HR 0.54) were considered to improve the PFS. Meanwhile, the risk of disease progression was only reduced for patients with relapsed/refractory MM (HR 0.70) but not for newly diagnosed/untreated MM (HR 0.93). Finally, the risk of serious adverse events (RR 1.12) and the risk of infection (RR 1.09) and cardiac disorders (RR 1.32) were higher for the experimental group compared to the control group.

Conclusions: Our findings showed that Elotuzumab combination therapy prolonged OS and PFS compared to non-Elotuzumab treatments in patients with MM. However, further investigations are required to establish the most effective combination of the Elotuzumab regimen.

查看原文本刊更多论文

Elotuzumab联合治疗多发性骨髓瘤患者的安全性和有效性:一项系统评价和荟萃分析。

目的:我们评估免疫刺激单克隆抗体Elotuzumab与伴随治疗方案联合治疗多发性骨髓瘤(MM)患者的有效性和安全性。研究设计和方法:系统检索PubMed、Scopus、Web of Science和EMBASE数据库，截止到2022年8月2日。结果:纳入5项随机对照试验，共1763名受试者。与非Elotuzumab方案相比，Elotuzumab联合治疗的PFS和OS分别提高了14%(风险比[HR] 0.86)和20% (HR 0.80)。来那度胺+地塞米松方案(HR 0.82)或泊马度胺+地塞米松方案(HR 0.54)中加入Elotuzumab可改善PFS。同时，只有复发/难治性MM患者的疾病进展风险降低(HR 0.70)，而新诊断/未治疗的MM患者的疾病进展风险没有降低(HR 0.93)。最后，实验组的严重不良事件风险(RR 1.12)、感染风险(RR 1.09)和心脏疾病风险(RR 1.32)均高于对照组。结论:我们的研究结果显示，与非埃洛妥珠单抗治疗相比，埃洛妥珠单抗联合治疗延长了MM患者的OS和PFS。然而，需要进一步的研究来确定埃洛妥珠单抗最有效的联合治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.